Interpreting Steep Dose-Response Curves in Early Inhibitor Discovery
- 10 November 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (25) , 7274-7277
Abstract
Many screening hits inhibit enzymes with steep dose-response curves, which are considered pathological. Three models might explain these curves: multisite binding, an inhibitor phase transition, or stoichiometric inhibition caused by a high enzyme to Kd ratio. Experiments with promiscuous aggregators, for which steep curves are common, suggest that these curves owe to stoichiometric inhibition, which predicts that IC50 should vary linearly with enzyme concentration. Most steep dose-response curves in screening may be due to this effect.Keywords
This publication has 11 references indexed in Scilit:
- Quantitative high-throughput screening: A titration-based approach that efficiently identifies biological activities in large chemical librariesProceedings of the National Academy of Sciences, 2006
- Screening in a spirit haunted worldDrug Discovery Today, 2006
- Navigating chemical space for biology and medicineNature, 2004
- Exploring biology with small organic moleculesNature, 2004
- Identification and Prediction of Promiscuous Aggregating Inhibitors among Known DrugsJournal of Medicinal Chemistry, 2003
- Designing screens: how to make your hits a hitNature Reviews Drug Discovery, 2003
- Nonleadlikeness and leadlikeness in biochemical screeningDrug Discovery Today, 2003
- Three-Dimensional Structure of AmpC β-Lactamase from Escherichia coli Bound to a Transition-State Analogue: Possible Implications for the Oxyanion Hypothesis and for Inhibitor DesignBiochemistry, 1998
- A Personal View of PharmacologyAnnual Review of Pharmacology and Toxicology, 1996
- ZONE BEHAVIOR OF ENZYMESJournal of General Physiology, 1943